Spyre Therapeutics AGLE Stock
Spyre Therapeutics Price Chart
Spyre Therapeutics AGLE Financial and Trading Overview
| Spyre Therapeutics stock price | 12.01 USD |
| Previous Close | 0.15 USD |
| Open | 0.15 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 1000 |
| Day's Range | 0.14 - 0.15 USD |
| 52 Week Range | 0.11 - 1.56 USD |
| Volume | 398.05K USD |
| Avg. Volume | 817.69K USD |
| Market Cap | 9.58M USD |
| Beta (5Y Monthly) | 1.748416 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.12 USD |
AGLE Valuation Measures
| Enterprise Value | -25284048 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.8312501 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 8.223516 |
| Price/Book (mrq) | 0.28446603 |
| Enterprise Value/Revenue | -21.703 |
| Enterprise Value/EBITDA | 0.326 |
Trading Information
Spyre Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.748416 |
| 52-Week Change | -77.38% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.56 USD |
| 52 Week Low | 0.11 USD |
| 50-Day Moving Average | 0.16 USD |
| 200-Day Moving Average | 0.46 USD |
AGLE Share Statistics
| Avg. Volume (3 month) | 817.69K USD |
| Avg. Daily Volume (10-Days) | 563.36K USD |
| Shares Outstanding | 65.4M |
| Float | 39.48M |
| Short Ratio | 0.76 |
| % Held by Insiders | 1.99% |
| % Held by Institutions | 69.83% |
| Shares Short | 334.17K |
| Short % of Float | 0.52% |
| Short % of Shares Outstanding | 0.50% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -6793.64% |
| Gross Margin | -128.92% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -72.94% |
| Return on Equity (ttm) | -163.26% |
Income Statement
| Revenue (ttm) | 1.17M USD |
| Revenue Per Share (ttm) | 0.01 USD |
| Quarterly Revenue Growth (yoy) | -85.50% |
| Gross Profit (ttm) | -262000 USD |
| EBITDA | -77598000 USD |
| Net Income Avi to Common (ttm) | -77801000 USD |
| Diluted EPS (ttm) | -0.87 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 38.48M USD |
| Total Cash Per Share (mrq) | 0.59 USD |
| Total Debt (mrq) | 4.43M USD |
| Total Debt/Equity (mrq) | 13.17 USD |
| Current Ratio (mrq) | 3.512 |
| Book Value Per Share (mrq) | 0.515 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -71515000 USD |
| Levered Free Cash Flow (ttm) | -45038248 USD |
Profile of Spyre Therapeutics
| Country | United States |
| State | TX |
| City | Austin |
| Address | 805 Las Cimas Parkway |
| ZIP | 78746 |
| Phone | 512 942 2935 |
| Website | https://www.aeglea.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 61 |
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Q&A For Spyre Therapeutics Stock
What is a current AGLE stock price?
Spyre Therapeutics AGLE stock price today per share is 12.01 USD.
How to purchase Spyre Therapeutics stock?
You can buy AGLE shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Spyre Therapeutics?
The stock symbol or ticker of Spyre Therapeutics is AGLE.
Which industry does the Spyre Therapeutics company belong to?
The Spyre Therapeutics industry is Biotechnology.
How many shares does Spyre Therapeutics have in circulation?
The max supply of Spyre Therapeutics shares is 4.05M.
What is Spyre Therapeutics Price to Earnings Ratio (PE Ratio)?
Spyre Therapeutics PE Ratio is 0.00000000 now.
What was Spyre Therapeutics earnings per share over the trailing 12 months (TTM)?
Spyre Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Spyre Therapeutics company belong to?
The Spyre Therapeutics sector is Healthcare.
Spyre Therapeutics AGLE included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17019.88 USD — |
+0.59
|
5.94B USD — | 16917.51 USD — | 17032.66 USD — | — - | 5.94B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 2247.92 USD — |
-0.06
|
— — | 2233.52 USD — | 2269.56 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4363.67 USD — |
-1.28
|
— — | 4335.6 USD — | 4436.05 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 978.74 USD — |
-1.03
|
— — | 973.64 USD — | 990.74 USD — | — - | — — |
- {{ link.label }} {{link}}